S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Comprehensive Analysis of PayPal Stock
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
MarketBeat Week in Review – 4/15 - 4/19
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Comprehensive Analysis of PayPal Stock
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
MarketBeat Week in Review – 4/15 - 4/19
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Comprehensive Analysis of PayPal Stock
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
MarketBeat Week in Review – 4/15 - 4/19
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Comprehensive Analysis of PayPal Stock
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
MarketBeat Week in Review – 4/15 - 4/19

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$1.05
-11.0%
$2.02
$0.39
$18.00
$5.60M3.523,351 shs10,732 shs
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$0.08
+15.2%
$0.53
$0.07
$23.40
$381K1.3302,299 shs196,527 shs
Neovasc Inc. stock logo
NVCN
Neovasc
$30.03
$29.69
$4.59
$30.07
$82.28M1.756,993 shs1 shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$3.29
+1.2%
$3.89
$1.79
$5.38
$53.92M0.9182,791 shs93,323 shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$3.80
-0.8%
$3.89
$1.03
$5.07
$113.92M2.44180,665 shs48,573 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
-11.54%-30.46%-45.03%-79.29%-70.00%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
+8.29%-71.29%-85.42%-93.05%-99.41%
Neovasc Inc. stock logo
NVCN
Neovasc
0.00%0.00%0.00%0.00%0.00%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
+1.23%-2.66%-10.35%+26.05%-34.85%
Neuronetics, Inc. stock logo
STIM
Neuronetics
-0.78%-12.04%-11.63%+14.46%+74.31%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
1.8597 of 5 stars
3.55.00.00.00.90.00.6
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
2.2841 of 5 stars
3.55.00.00.00.00.81.3
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.8899 of 5 stars
3.33.00.00.02.11.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
3.00
Buy$28.8837,993.67% Upside
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.00
Buy$7.50127.96% Upside
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.50
Moderate Buy$8.00110.53% Upside

Current Analyst Ratings

Latest MOTS, STIM, SRTS, ARTH, and NVCN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/26/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/6/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00 ➝ $8.00
(Data available from 4/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$80K62.21N/AN/A($2.43) per share-0.43
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$320K1.19N/AN/A$1.74 per share0.04
Neovasc Inc. stock logo
NVCN
Neovasc
$3.81M21.60N/AN/A$5.77 per share5.20
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$24.41M2.21$0.06 per share56.28$2.98 per share1.10
Neuronetics, Inc. stock logo
STIM
Neuronetics
$71.35M1.60N/AN/A$1.18 per share3.22

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
-$6.98MN/A0.00N/A-6,809.45%N/A-386.74%5/20/2024 (Estimated)
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
-$12.87M-$28.55N/AN/A-4,033.54%N/A-110.70%5/8/2024 (Estimated)
Neovasc Inc. stock logo
NVCN
Neovasc
-$41.20M-$15.08N/AN/A-1,082.92%-127.25%-80.31%N/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$490K$0.03109.70N/A1.99%1.04%0.93%5/9/2024 (Confirmed)
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$30.19M-$1.07N/AN/AN/A-42.31%-72.76%-29.25%5/14/2024 (Estimated)

Latest MOTS, STIM, SRTS, ARTH, and NVCN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
-$0.04N/A+$0.04N/AN/AN/A  
3/18/2024Q4 2023
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/A-$4.13-$4.13-$3.78N/A$0.06 million
3/5/202412/31/2023
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.26-$0.19+$0.07-$0.19$19.73 million$20.31 million    
2/20/2024Q1 2024
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A-$0.57-$0.57-$0.57N/A$0.05 million
2/8/2024Q4 2023
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.12$0.26+$0.14$0.26$12.10 million$12.57 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/AN/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A
0.16
0.04
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
0.46
1.76
1.69
Neovasc Inc. stock logo
NVCN
Neovasc
0.80
2.96
2.85
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
11.76
8.23
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.73
4.73
4.33

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
6.91%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
20.06%
Neovasc Inc. stock logo
NVCN
Neovasc
1.64%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%

Insider Ownership

CompanyInsider Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
4.50%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
1.57%
Neovasc Inc. stock logo
NVCN
Neovasc
N/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
11.10%
Neuronetics, Inc. stock logo
STIM
Neuronetics
7.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
84.74 million4.53 millionNot Optionable
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
155.03 million4.95 millionNot Optionable
Neovasc Inc. stock logo
NVCN
Neovasc
492.74 millionN/ANot Optionable
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3516.39 million14.57 millionOptionable
Neuronetics, Inc. stock logo
STIM
Neuronetics
20329.98 million27.79 millionOptionable

MOTS, STIM, SRTS, ARTH, and NVCN Headlines

SourceHeadline
Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%
marketbeat.com - April 12 at 3:58 PM
New Study Offers Hope for Depression Patients Undergoing TMS TherapyNew Study Offers Hope for Depression Patients Undergoing TMS Therapy
msn.com - April 12 at 1:57 AM
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalNew Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
globenewswire.com - April 10 at 8:31 AM
Kent Lake Capital LLC Has $3.24 Million Stake in Neuronetics, Inc. (NASDAQ:STIM)Kent Lake Capital LLC Has $3.24 Million Stake in Neuronetics, Inc. (NASDAQ:STIM)
marketbeat.com - April 6 at 7:36 PM
Neuronetics Stock (NASDAQ:STIM), Quotes and News SummaryNeuronetics Stock (NASDAQ:STIM), Quotes and News Summary
benzinga.com - April 5 at 5:38 AM
Neuronetics (STIM) FDA-Cleared NeuroStar to Aid in DepressionNeuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
zacks.com - April 1 at 11:56 AM
Neuronetics Bolsters Talent Pool with Strategic Stock Incentives for New HiresNeuronetics Bolsters Talent Pool with Strategic Stock Incentives for New Hires
msn.com - April 1 at 1:05 AM
Neurostar cleared for use in adolescent depressionNeurostar cleared for use in adolescent depression
bioworld.com - March 29 at 12:15 AM
FDA grants clearance to TMS device, NeuroStar as adjunct to first line depression treatmentFDA grants clearance to TMS device, NeuroStar as adjunct to first line depression treatment
medicaldialogues.in - March 29 at 12:15 AM
FDA Clears NeuroStars TMS Therapy for Adolescents with Major Depressive DisorderFDA Clears NeuroStar's TMS Therapy for Adolescents with Major Depressive Disorder
msn.com - March 29 at 12:15 AM
Neuronetics, Inc. (NASDAQ:STIM) Short Interest UpdateNeuronetics, Inc. (NASDAQ:STIM) Short Interest Update
marketbeat.com - March 28 at 11:57 AM
Neuronetics wins FDA clearance for device to treat adolescents with depressionNeuronetics wins FDA clearance for device to treat adolescents with depression
finance.yahoo.com - March 27 at 4:43 PM
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - March 27 at 4:43 PM
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - March 27 at 4:30 PM
Buy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD MarketBuy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD Market
markets.businessinsider.com - March 27 at 6:41 AM
Neuronetics’ magnetic stimulation cleared as first-line add-on therapy for adolescents with severe depressionNeuronetics’ magnetic stimulation cleared as first-line add-on therapy for adolescents with severe depression
fiercebiotech.com - March 27 at 6:41 AM
Neuronetics (STIM) "Market Perform" Rating Reiterated at William BlairNeuronetics' (STIM) "Market Perform" Rating Reiterated at William Blair
marketbeat.com - March 26 at 3:29 PM
TMS Device NeuroStar Cleared as Add-On Treatment for Adolescent DepressionTMS Device NeuroStar Cleared as Add-On Treatment for Adolescent Depression
empr.com - March 26 at 3:49 AM
Neuronetics’s NeuroStar wins FDA clearance for adolescents with depressionNeuronetics’s NeuroStar wins FDA clearance for adolescents with depression
msn.com - March 25 at 10:48 PM
Neuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with DepressionNeuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
finanznachrichten.de - March 25 at 12:07 PM
Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21
marketwatch.com - March 25 at 12:07 PM
Neuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New IndicationNeuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New Indication
markets.businessinsider.com - March 25 at 12:07 PM
FDA clears Neuronetics’ neurostim for adolescents with depressionFDA clears Neuronetics’ neurostim for adolescents with depression
massdevice.com - March 25 at 12:07 PM
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with DepressionNeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
globenewswire.com - March 25 at 8:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Arch Therapeutics logo

Arch Therapeutics

OTCMKTS:ARTH
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.
Motus GI logo

Motus GI

NASDAQ:MOTS
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. Motus GI Holdings, Inc. was founded in 2008 and is based in Fort Lauderdale, Florida.
Neovasc logo

Neovasc

NASDAQ:NVCN
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.
Sensus Healthcare logo

Sensus Healthcare

NASDAQ:SRTS
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Neuronetics logo

Neuronetics

NASDAQ:STIM
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.